Pulmonary Embolism

31Dec

Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial

Posted by: admin Categories: Pulmonary Embolism

Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial – Fingerprint — University of Edinburgh Research Explorer Sort by Weight Alphabetically Medicine & Life Sciences Rivaroxaban 100% Aortic Diseases 94% Warfarin 80% Mitral Valve 76% Aortic […]

24Dec

Use of rivaroxaban in sickle cell disease and venous thromboembolism: A case report

Posted by: admin Categories: Pulmonary Embolism

Introduction: Sickle cell disease (SCD) is a hematological disorder characterized by sickling of red blood cells. Patients are at increased risk of venous thromboembolism. There are no guidelines for the management of venous thromboembolism in sickle cell disease specifically in terms of the anticoagulant of choice. Patient concerns: Here, we report a case of a […]

23Dec

Apixaban linked to lower bleeding risk than rivaroxaban for patients with nonvalvular AFib

Posted by: admin Categories: Pulmonary Embolism

Primary outcomes included all-cause hospitalization, stroke and major bleeding, stroke and systemic embolism. Overall, the authors found that the adjusted hazard ratio from the meta-regression analyses was 0.88 to 0.95, indicating a significantly lower hazard of stroke/systemic embolism associated with apixaban compared with rivaroxaban. The authors also found that pair-wise meta-analyses showed that the pooled […]

21Dec

Comparison of Direct Oral Anticoagulants for Acute Hospital Mortality in Venous Thromboembolism

Posted by: admin Categories: Pulmonary Embolism

This article was originally published here Am J Cardiovasc Drugs. 2021 Dec 20. doi: 10.1007/s40256-021-00514-5. Online ahead of print. ABSTRACT BACKGROUND: The choice of direct oral anticoagulants (DOACs) for venous thromboembolism (VTE) is at the physician’s discretion; however, it is useful to know the differences in the clinical data of DOACs to help physicians choose. […]

18Dec

Hematologic Flashcards | Quizlet

Posted by: admin Categories: Pulmonary Embolism

Hematologic Flashcards | Quizlet heparinwarfarin Factor Xa inhibitors -Myocardial infarction-ischemic stroke-DVT/PE-atrial fibrillation -after surgery-extended immobilization -treat DVT-MOA: increase antithrombin activity which binds and inactivates clotting factors (thrombin, IXa, Xa)-IV or injection: rapid onset -MUST monitor INR, partial thromboplastin, and platelets -side effects: bleeding (thrombocytopenia) -treat long term prevention of DVT and treat a-fib-MOA: interferes […]

17Dec

Recurrent VTE and Bleeding With Apixaban vs. Rivaroxaban

Posted by: admin Categories: Pulmonary Embolism

Quick Takes More than 36,000 patients with VTE newly starting apixaban or rivaroxaban were compared and followed for >3 months using medical claims. Use of apixaban was associated with a lower risk of intracranial or gastrointestinal bleeding as compared to rivaroxaban therapy. Use of apixaban was associated with a lower risk of recurrent VTE as […]

16Dec

Daily Medication Pearl: Dabigatran Etexilate (Pradaxa)

Posted by: admin Categories: Pulmonary Embolism

Dabigatran and its acyl glucuronides are competitive, direct thrombin inhibitors. Medication Pearl of the Day: Dabigatran Etexilate (Pradaxa) Indication: Dabigatran etexilatecapsules is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in […]

Tags: surgery

15Dec

[Solved] False Question 2 0 out of 10 points Please use the nomogram provided in the Anticoagulants PPT for reference. You patient is on a heparin in…

Posted by: admin Categories: Pulmonary Embolism

False Question 2 0 out of 10 points Please use the nomogram… Image transcription text False Question 2 0 out of 10 points Please use the nomogram provided in the Anticoagulants PPT for reference. You patient is on a heparin infusion for treatment of a pulmonary embolism. Pt weight 220 pounds. Your patient is currently […]

9Dec

Cancer-Associated ThrOmboSIs – Patient-Reported OutcoMes With RivarOxaban (COSIMO) – Baseline characteristics and clinical outcomes

Posted by: admin Categories: Pulmonary Embolism

This article was originally published here Res Pract Thromb Haemost. 2021 Nov 30;5(8):e12604. doi: 10.1002/rth2.12604. eCollection 2021 Dec. ABSTRACT BACKGROUND: Patients with cancer-associated thrombosis (CAT) have a high risk of recurrent venous thromboembolic events, which contribute to significant morbidity and mortality. Direct oral anticoagulants may provide a convenient treatment option for these patients. OBJECTIVES: To […]

7Dec

Apixaban shows superior effectiveness, safety compared to rivaroxaban | ACP Internist Weekly

Posted by: admin Categories: Pulmonary Embolism

Patients with venous thromboembolism (VTE) who received apixaban had a lower rate of recurrence, as well as intracranial and gastrointestinal bleeding events, compared with those treated with rivaroxaban, a recent study found. The retrospective new-user cohort study used a U.S.-based commercial health care insurance database to compare outcomes between patients with VTE who were newly […]

7Dec

Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data

Posted by: admin Categories: Pulmonary Embolism

Background: Apixaban and rivaroxaban are replacing vitamin K antagonists for the treatment of venous thromboembolism (VTE) in adults; however, head-to-head comparisons remain limited. Objective: To assess the effectiveness and safety of apixaban compared with rivaroxaban in patients with VTE. Design: Retrospective new-user cohort study. Setting: U.S.-based commercial health care insurance database from 1 January 2015 […]

25Nov

Alembic Pharmaceuticals announces US FDA tentative approval for Dabigatran Etexilate capsules

Posted by: admin Categories: Pulmonary Embolism

The tentatively approved ANDA is therapeutically equivalent to the Reference Listed Drug (RLD) product Pradaxa Dabigatran Etexilate Mesylate capsules, Eq to 150 mg base, Boehringer Ingelheim Read Article Alembic Pharmaceuticals yesterday announced that it has received tentative approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Dabigatran […]

22Nov

To aPTT or not to aPTT: Evaluating the optimal monitoring strategy for unfractionated heparin

Posted by: admin Categories: Pulmonary Embolism

Anticoagulation is widely used in the inpatient setting for various indications for both surgical and medical patients including stroke prevention in non-valvular atrial fibrillation, prevention of venous thromboembolism in post-surgical patients, management of acute coronary syndromes, and treatment of acute thrombosis. For patients with acute thrombosis, anticoagulation is the key therapy to stabilize the thrombus, […]

18Nov

Incidence of thrombotic complications related to weight-based dosing of activated prothrombin complex concentrate (aPCC) for reversal of apixaban and rivaroxaban in obese patients by Caitlyn Whitaker

Posted by: admin Categories: Pulmonary Embolism

Factor eight inhibitor bypassing activity (aPCC) is recommended as a non-specific reversal agent for direct oral anticoagulants (DOACs) according to the 2017 American College of Cardiology (ACC) guidelines for reversal of anticoagulation. Factor eight inhibitor bypassing activity carries a black box warning for thrombotic events such as stroke, pulmonary embolism, deep vein thrombosis, and myocardial […]

17Nov

What is Standard Dose of Rivaroxaban in Elderly Asian Patients with Atrial Fibrillation: 20ms versus. 15mg?

Posted by: admin Categories: Pulmonary Embolism

Although there is no age criterion for rivaroxaban dose reduction, elderly patients with atrial fibrillation (AF) are often prescribed an off-label reduced dose. We aimed to evaluate whether age is a necessary criterion for rivaroxaban dose reduction in Korean patients with AF. Among 2208 patients who prescribed warfarin or rivaroxaban, 552 patients over 75 years […]

12Nov

Notes.docx – Heparin MOA binds irreversibly to the endogenous antithrombin III through a key pentasaccride accelerating the action of antithrombin III

Posted by: admin Categories: Pulmonary Embolism

Heparin  MOA: binds irreversibly to the endogenous antithrombin III through a key pentasaccride accelerating the action of antithrombin III by 1000 folds leading to increased inactivation of factor X and factor III  Clinical uses o Quick reversal of thrombosis o Venous thrombosis o Pulmonary embolism o Acute coronary syndromes  Limiations o Bind […]

11Nov

Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER

Posted by: admin Categories: Pulmonary Embolism

Background Thromboprophylaxis extended after hospital discharge in medically ill patients currently is not recommended by practice guidelines because of uncertainty about the benefit for preventing major or fatal thromboembolic events, and the risk of bleeding. Methods and Results We assessed the benefit and risk of thromboprophylaxis with rivaroxaban 10 mg once daily extended for 25 […]

9Nov

Rivaroxaban Shows Superiority to Aspirin in Lowering Risk of Recurrent Stroke in Patients With Left Ventricular Dysfunction

Posted by: admin Categories: Pulmonary Embolism

Rivaroxaban (Xarelto; Janssen) found superior to aspirin in reducing the risk of recurrent stroke or systemic embolism in patients with left ventricular dysfunction. Data from the phase 3 NAVIGATE ESUS trial indicate that rivaroxaban (Xarelto; Janssen) is superior to aspirin in decreasing the risk of recurrent stroke or systemic embolism in patients with left ventricular […]

9Nov

Week 6 Pre-lab Assignment.docx – Week 6 Pre-lab Assignment Directions Along with answering each question below provide a supporting rationale for it The

Posted by: admin Categories: Pulmonary Embolism

Week 6 Pre-lab Assignment Directions: Along with answering each question below, provide a supporting rationale for it. The responses must be sourced with an appropriate reference in proper APA format. 1. The doctor has prescribed heparin for your patient, which belongs to what specific category/class of medications? Why (based on its action)?  Anticoagulant. Binding […]

Tags: surgery

6Nov

Rivaroxaban Superior to Aspirin in Reducing Recurrent Stroke Risk in Left Ventricular Dysfunction

Posted by: admin Categories: Pulmonary Embolism

Post-hoc analysis from the phase 3 NAVIGATE ESUS trial (NCT02313909) provided evidence that rivaroxaban (Xarelto; Janssen), an anticoagulant, was superior to aspirin at reducing the risk of recurrent stroke or systemic embolism in patients with left ventricular (LV) dysfunction. Led by Alexander E. Merkler, MD, MS, assistant professor of neurology, Weill Cornell Medicine, the study […]

Latest Tweets

Breathing+ by Breathing Labs has passed peer review in a randomized controlled clinical trial that was recently pub… twitter.com/i/web/status/15431…
July 2, 2022 11:37 am
BREAKING: @breathinglabs and @Nintendo clinical trial is published in journal Pediatric Pulmonology (SCI Q2, Impact… twitter.com/i/web/status/15404…
June 24, 2022 10:20 pm
Clinical mouthpieces 10pcs packages are now available at 45€/50USD (shipping cost not included). Learn more:… twitter.com/i/web/status/15000…
March 5, 2022 10:56 am
BREATHING VR: Lately we are sourcing this VR headset for use in Breathing VR application. It allows easiest install… twitter.com/i/web/status/13990…
May 30, 2021 3:52 pm
Update: Each purchase of Breathing+ will now include three machine washable mouthpieces. Previous buyers will be su… twitter.com/i/web/status/13328…
November 28, 2020 10:41 pm
Update: We moved servers + relocated all our games to our servers, please be patient while google reviews all that… twitter.com/i/web/status/13237…
November 3, 2020 7:31 pm
Registration and all functionalities at breathinglabs.com (and in our iOS and Android games) are fixed and fu… twitter.com/i/web/status/12407…
March 19, 2020 10:50 pm
We are back in stock with Breathing+, currently searching for VR supplier, and setting up mass production for toys… twitter.com/i/web/status/11717…
September 11, 2019 12:00 pm
BREAKING: Nintendo Co. Ltd (Japan) is implementing Breathing Games by @breathinglabs in FDA approved clinical trial… twitter.com/i/web/status/11580…
August 4, 2019 5:55 pm